Skip to main content

Table 4 Overall and subgroups meta-analysis of COX-2 rs5275 polymorphism and HNSCC risk

From: COX-2 rs689466, rs5275, and rs20417 polymorphisms and risk of head and neck squamous cell carcinoma: a meta-analysis of adjusted and unadjusted data

Overall and subgroups

No.

OR (95 % CI)

Heterogeneity (I2%/p)

C vs. T (unadjusted and adjusted)

 Overall (unadjusted)

4

0.92 (0.81–1.04)

1 %/0.38

 Overall (adjusted)

2

1.06 (0.81–1.40)

0 %/0.33

 HWE (Yes–unadjusted)

3

0.94 (0.82–1.06)

0 %/0.45

 HWE (No–unadjusted)

1

0.69 (0.42–1.11)

NA

 Asians (unadjusted)

3

0.97 (0.87–1.16)

17 %/0.30

 Asians (adjusted)

2

1.06 (0.81–1.40)

0 %/0.33

 Caucasian (unadjusted)

1

0.87 (0.74–1.04)

NA

 OSCC (unadjusted)

3

0.90 (0.76–1.06)

0 %/0.52

 OSCC (adjusted)

1

0.88 (0.55–1.40)

NA

 LSCC (unadjusted)

2

0.88 (0.73–1.06)

47 %/0.17

CC vs. TT (unadjusted and adjusted)

 Overall (unadjusted)

4

0.92 (0.67–1.27)

36 %/0.19

 Overall (adjusted)

4

0.92 (0.67–1.27)

49 %/0.12

 HWE (Yes–unadjusted)

3

0.89 (0.64–1.24)

47 %/0.15

 HWE (No–unadjusted)

1

2.59 (0.31–21.82)

NA

 Asians (unadjusted)

3

1.49 (0.87–2.57)

0 %/0.86

 Asians (adjusted)

3

1.45 (0.81–2.59)

16 %/0.30

 Caucasian (unadjusted)

1

0.71 (0.47–1.07)

NA

 Caucasian (adjusted)

1

0.75 (0.51–1.10)

NA

 OSCC (unadjusted)

3

0.92 (0.59–1.43)

0 %/0.48

 OSCC (adjusted)

3

0.89 (0.56–1.40)

0 %/0.57

 LSCC (unadjusted)

2

0.98 (0.35–2.75)

67 %/0.08

 LSCC (adjusted)

2

0.88 (0.34–2.26)

60 %/0.12

CC vs. CT (unadjusted and adjusted)

 Overall (unadjusted)

4

1.02 (0.74–1.41)

48 %/0.12

 Overall (adjusted)

4

0.99 (0.84–1.16)

0 %/0.60

 HWE (Yes–unadjusted)

3

0.96 (0.68–1.33)

42 %/0.18

 HWE (No–unadjusted)

1

5.13 (0.61–42.88)

NA

 Asians (unadjusted)

3

1.73 (0.99–3.01)

0 %/0.54

 Asians (adjusted)

3

0.93 (0.73–1.19)

0 %/0.49

 Caucasian (unadjusted)

1

0.77 (0.52–1.16)

NA

 Caucasian (adjusted)

1

1.03 (0.82–1.28)

NA

 OSCC (unadjusted)

3

0.99 (0.64–1.53)

44 %/0.17

 OSCC (adjusted)

3

1.02 (0.80–1.30)

28 %/0.25

 LSCC (unadjusted)

2

0.87 (0.54–1.40)

50 %/0.16

 LSCC (adjusted)

2

0.92 (0.70–1.21)

0 %/0.62

CC vs. CT + TT (unadjusted)

 Overall

4

0.96 (0.70–1.31)

43 %/0.15

 HWE (Yes)

3

0.91 (0.66–1.25)

46 %/0.16

 HWE (No)

1

3.65 (0.45–29.89)

NA

 Asians

3

1.58 (0.93–2.71)

0 %/0.70

 Caucasian

1

0.74 (0.50–1.09)

NA

 OSCC

3

0.94 (0.62–1.43)

16 %/0.30

 LSCC

2

1.02 (0.40–2.60)

63 %/0.10

CC + CT vs. TT (unadjusted and adjusted)

 Overall (unadjusted)

4

0.90 (0.77–1.04)

0 %/0.41

 Overall (adjusted)

3

0.98 (0.84–1.15)

0 %/0.78

 HWE (Yes–unadjusted)

3

0.92 (0.79–1.08)

0 %/0.74

 HWE (No–unadjusted)

1

0.57 (0.30–1.05)

NA

 Asians (unadjusted)

3

0.91 (0.74–1.12)

29 %/0.25

 Asians (adjusted)

2

1.00 (0.79–1.27)

0 %/0.49

 Caucasian (unadjusted)

1

0.88 (0.70–1.10)

NA

 Caucasian (adjusted)

1

0.97 (0.78–1.20)

NA

 OSCC (unadjusted)

3

1.09 (0.55–2.16)

91 %/<0.05

 OSCC (adjusted)

2

1.01 (0.80–1.27)

2 %/0.31

 LSCC (unadjusted)

2

0.87 (0.68–1.10)

7 %/0.30

 LSCC (adjusted)

2

0.89 (0.69–1.15)

0 %/0.35

  1. OSCC oral squamous cell carcinoma; HNSCC head and neck squamous cell carcinoma; LSCC laryngeal squamous cell carcinoma; OR odds ratio; CI confidence interval; NA not available; HWE Hardy–Weinberg Equilibrium